Oncogenic KRAS mutation is the key regulator in pancreatic cancer maintenance.4,6 Many receptors for growth factors and cytokines are able to activate KRAS either by direct or indirect protein interaction.4,6 Similarly, we demonstrated that hypoxia increases the interaction between RAGE and KRAS in pancreatic tumor cells. The gene discussed is AGER; the disease is pancreatic neoplasm.